Global Chlamydia Treatment Market Highlights 2022 – 2030
The global chlamydia treatment market is estimated to garner a large amount of revenue and grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence chlamydia and other sexually transmitted diseases, and rise in demand for screening of the disease among people all around the world. According to the World Health Organization, each year, there are an estimated 376 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. Also, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Along with these, growing number of government initiatives and free diagnostic camps for spreading awareness about sexually transmitted infections is also predicted to be a significant factor driving market growth in the near future. Furthermore, favorable reimbursement policies for companies are evaluated to give impetus to research and development activities associated with the development of novel drugs, which in turn is projected to offer lucrative opportunities for market growth in the forthcoming years.
Get more information on this report: Download Sample PDF
The market is segmented by test type into culture tests, nucleic acid amplification test (NAAT), direct fluorescent antibody test, serology tests, and others, out of which, the nucleic acid amplification test (NAAT) segment is anticipated to hold the largest share in the global chlamydia treatment market. This can be accounted to the high accuracy of the test in screening the disease. Apart from these, NAATs allow screening of large number of males and females using self-collected vaginal swabs or using urine without the requirement of a pelvic examination. Additionally, on the basis of route of administration, the oral segment is assessed to acquire the largest share over the forecast period owing to the non-invasive nature, ease of convenience, and cost-effectiveness of this type of route for drug administration.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Chlamydia Treatment Market Regional Synopsis
On the basis of geographical analysis, the global chlamydia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing demand for medical screening and burgeoning need for raising awareness about STIs. In addition, rapid growth of biopharmaceutical industry and rising government support for improving the healthcare infrastructure are also anticipated to drive the region’s market growth in the future. Moreover, the market in North America is projected to grab the largest share during the forecast period ascribing to the high adoption rate of medical screening, high prevalence of STDs, and presence of a large number of pharmaceutical and biopharmaceutical companies in the region. As per the Centers for Disease Control and Prevention, in 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States for that year.
Get more information on this report: Download Sample PDF
The global chlamydia treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global chlamydia treatment market includes the following segments:
By Test Type
- Culture Tests
- Nucleic Acid Amplification Test (NAAT)
- Direct Fluorescent Antibody Test
- Serology Tests
- Others
By Route of Administration
- Oral
- Injectable
- Others
By End User
- Hospitals
- Diagnostic Centers
- Ambulatory Surgical Centers
- Others
Growth Drivers
- Increasing Prevalence of Sexually Transmitted Diseases Globally
- Rising Demand for Screening of the Disease
Challenges
- Social Stigma Associated with STIs
Top Featured Companies Dominating the Market
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline Plc
- AstraZeneca plc
- Gilead Sciences Inc.
- Sanofi Group
- Teva Pharmaceuticals
- Novartis AG
- Abbott Laboratories
- Hologic, Inc.
- Johnson & Johnson Services, Inc.
